1,987
Views
4
CrossRef citations to date
0
Altmetric
Research Papers

Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer

, , , , , , & show all
Pages 1995-2003 | Received 06 May 2022, Accepted 03 Jul 2022, Published online: 14 Jul 2022

References

  • Bollschweiler E, Plum P, Mönig SP, et al. Current and future treatment options for esophageal cancer in the elderly. Expert Opin Pharmacother 2017;18:1001–10.
  • Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg 2018;41:210–5.
  • Qin B, Dong M, Wang Z, et al. Long non-coding RNA CASC15 facilitates esophageal squamous cell carcinoma tumorigenesis via decreasing SIM2 stability via FTO-mediated demethylation. Oncol Rep 2021;45:1059–71.
  • Cui Y, Zhang C, Ma S, et al. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2021;40:294.
  • Liu S, Huang M, Chen Z, et al. FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res 2020;389:111894.
  • Dobie C, Montgomery AP, Szabo R, et al. Synthesis and biological evaluation of selective phosphonate-bearing 1,2,3-triazole-linked sialyltransferase inhibitors. RSC Med Chem 2021;12:1680–9.
  • Srivastava A, Aggarwal L, Jain N. One-pot sequential alkynylation and cycloaddition: regioselective construction and biological evaluation of novel benzoxazole-triazole derivatives. ACS Comb Sci 2015;17:39–48.
  • Ashwini N, Garg M, Mohan CD, et al. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation. Bioorg Med Chem 2015;23:6157–65.
  • Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O’Farrill E, et al. Characterization of a dual Rac/Cdc42 inhibitor MBQ-167 in metastatic cancer. Mol Cancer Ther 2017;16:805–18.
  • Sahu R, Mishra R, Kumar R, et al. Pyridine moiety: an insight into recent advances in the treatment of cancer. Mini Rev Med Chem 2022;22:248–72.
  • Prakash M, Itoh Y, Fujiwara Y, et al. Identification of potent and selective inhibitors of fat mass obesity-associated protein using a fragment-merging approach. J Med Chem 2021;64:15810–24.
  • Shishodia S, Demetriades M, Zhang D, et al. Structure-based design of selective fat mass and obesity associated protein (FTO) inhibitors. J Med Chem 2021;64:16609–25.
  • Xu Z, Zhao SJ, Liu Y. 1,2,3-Triazole-containing hybrids as potential anticancer agents: current developments, action mechanisms and structure-activity relationships. Eur J Med Chem 2019;183:111700.
  • Haranahalli K, Honda T, Ojima I. Recent progress in the strategic incorporation of fluorine into medicinally active compounds. J Fluor Chem 2019;217:29–40.
  • Fu DJ, Liu YC, Yang JJ, et al. Design and synthesis of sulfonamide-1,2,3-triazole derivatives bearing a dithiocarbamate moiety as antiproliferative agents. J Chem Res 2017;41:523–5.
  • Zhou LL, Xu H, Huang Y, et al. Targeting the RNA demethylase FTO for cancer therapy. RSC Chem Bio 2021;2:1352–69.
  • Hirayama M, Wei FY, Chujo T, et al. FTO demethylates Cyclin D1 mRNA and controls cell-cycle progression. Cell Rep 2020;31:107464.
  • Wu R, Liu Y, Yao Y, et al. FTO regulates adipogenesis by controlling cell cycle progression via m6A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids 2018;1863:1323–30.
  • Tang Q, Lento A, Suzuki K, et al. Rab11-FIP1 mediates epithelial-mesenchymal transition and invasion in esophageal cancer. EMBO Rep 2021;22:e48351.
  • Loh CY, Chai JY, Tang TF, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells 2019;8:1118.
  • Zhang C, Zhang M, Ge S, et al. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. Cancer Med 2019;8:4766–81.
  • Liu Y, Wang R, Zhang L, et al. The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett 2017;13:4685–90.
  • Zhang L, Tong Z, Sun Z, et al. MiR-25-3p targets PTEN to regulate the migration, invasion, and apoptosis of esophageal cancer cells via the PI3K/AKT pathway. Biosci Rep 2020;40:BSR20201901.